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ABSTRACT
Cryptococcal infection is commonly seen in immunocompromised patients, although immunocompetent patients may also 
be infected. The pathogen’s portal of entry is the respiratory tract; however, the central nervous system is predominantly 
involved. Pulmonary involvement varies from interstitial and alveolar infiltrations to large masses, which are frequently 
first interpreted as lung neoplasm. The diagnosis of pulmonary cryptococcosis, in these cases, is frequently challenging, 
which, in most cases, requires histopathological examination. The authors report the case of a young female patient who 
presented a 20-day history of chest pleuritic pain and fever at the onset of symptoms. HIV serology was negative and 
CD4 count was normal. The imaging work-up was characterized by a huge opacity in the left inferior pulmonary lobe 
with a wide pleural base. Computed tomography showed a heterogeneous mass involving the bronchial tree. Mediastinal 
involvement was poor, and there was a splenomegaly. The patient underwent an exploratory thoracotomy and inferior 
lobectomy. The histopathological examination revealed a cryptococcoma. As the serum antigenemia was positive, the 
patient was scheduled for long-term treatment with fluconazole. The authors call attention to including the cryptococcal 
infection in the differential diagnosis of lung mass, mainly when localized in the lung bases in immunocompetent patients.
Keywords 
Cryptococcus; Lung diseases; Pulmonary Surgical Procedures; Therapeutics
CASE REPORT
A 17-year-old previously healthy Caucasian female 
patient sought the emergency unit complaining of left 
chest pleuritic pain during the last 20 days. She referred 
fever (axillary temperature of 38°C) at the onset of the 
symptoms but denied weight loss, sudoresis, cough, 
or any other systemic symptom. She had been initially 
treated with clarithromycin and levofloxacin because 
previous chest x-ray and computed tomography (CT) 
images interpreted the condition as pneumonia. 
After taking antibiotics, the fever ceased but pain 
did not improve. She underwent another course of 
antibiotics, this time with amoxicillin and clavulanate 
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for 10 days, which were similarly worthless. Therefore, 
she was hospitalized referring unchanged thoracic pain. 
Physical examination revealed a well-looking patient, 
afebrile, with normal hemodynamic parameters. Edema 
and lymphadenopathy were not present. Cardiac 
examination was normal, and pulmonary sounds were 
reduced in the left pulmonary base. Traube’s space was 
dull on percussion, but no organomegaly was palpable. 
Laboratory work-up was normal, and serologies for HIV, 
and hepatitis B and C were negative. The plain chest 
x-ray showed a well-circumscribed homogeneous round 
opacity, with a wide pleural base in the left inferior 
pulmonary lobe (Figure 1) that on the CT appeared 
as a nodular lesion with heterogeneous attenuation 
coefficient involving the bronchial tree in the left inferior 
lobe (Figure 2).
Splenomegaly was an additional finding on CT. 
Thoracic ultrasonography showed hypoechoic mass 
most probably of a solid nature. The bronchoscopy 
was normal and bronchoalveolar lavage (BAL) did 
not evidence acid-fast bacilli, fungus, or bacteria. The 
patient was submitted to an exploratory thoracotomy, 
which depicted a solid mass firmly adhered to the 
parietal pleura involving the left inferior lobe. The 
frozen biopsy, sampled from the non-necrotic tissue, 
revealed a dense histiocytic infiltration, but neither 
neoplastic nor inflammatory origins could be ruled 
out (Figure 3). An inferior lobectomy was undertaken 
(Figure 4), and the post-operative outcome was 
uneventful. The pathological examination revealed a 
firm heterogeneous mass, measuring 4.5 × 3.0 × 5.5 cm, 
intermingled with extensive necrotic areas (Figure 5).
Figure 1. Chest x-ray showing a homogeneous wide 
pleural base opacity in the inferior left pulmonary lobe.
Figure 2. Thoracic axial computed tomography showing 
a pulmonary mass with heterogeneous attenuation 
coefficient in the left lower lobe. A - Mediastinal 
window; B - Parenchymal window.
Figure 3. Photomicrography of the frozen biopsy. A - Pulmonary parenchyma showing a terminal bronchiole and 
vessel with altered architecture represented by total replacement of the alveolar tissue by a dense histiocytic infiltration 
(H&E, 100X); B - Detail of the foamy histiocytic infiltration replacing the alveolar parenchyma (H&E, 200X).
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The histology showed extensive foamy histiocyte 
infiltration, necrotic areas surrounded by granulomas 
with epitheliod histiocytes and multinucleated giant cells 
besides the presence of numerous round birefringent 
structures with a peripheral halo resembling fungus. 
The grocott and mucicarmine stainings were positive 
and diagnosed the structure as Cryptococcus sp 
(Figure 6). Thus, the final diagnosis was pulmonary 
cryptococcoma in an immunocompetent host. Brain 
computed tomography was normal, CD4 count was 
1200 cells/mm3 and the cryptococcal antigenemia 
was positive (quantitative determination was not 
performed), which pointed towards treatment with 
fluconazole.
Figure 4. Gross view of the left inferior pulmonary 
lobe. A - Hilar view; B - Pleural surface view, showing 
the pleural thickening adhered to the pulmonary 
parenchyma.
Figure 5. Gross view of the tumoral cross section 
showing yellowish necrotic areas.
DISCUSSION
Cryptococcus sp is an encapsulated fungus that 
may cause disease either in immunosuppressed or 
immunocompetent patients. The most pathogenic 
species are represented by C. neoformans and C. gattii; 
the former has a worldwide distribution infecting 
both immunocompetent and immunosuppressed 
hosts, while the latter is more prevalent in tropical and 
subtropical regions of the globe infecting mostly the 
immunocompetent hosts.1-3 In Brazil, Cryptococcus 
neoformans infections predominate the south and 
southeast regions, mostly associated with HIV infected 
patients, while Cryptococcus gattii predominates the 
north and northeast Brazilian states without evident 
association with immunosuppression.4
Cryptococcosis is more commonly seen in 
immunocompromised individuals, such as those with 
impaired cellular immunity like the HIV-infected patients, 
post-transplanted, chronic users of corticosteroids 
and/or immunosuppressant drugs or those patients with 
hematologic malignancies, sarcoidosis, or tuberculosis.3,5,6 
Among the patients with cryptococcosis without a known 
cause of immunosuppression, some impairment in the 
lymphocyte response to Cryptococcus sp as well as low 
CD4 count has been observed.1
The fungus, usually found in domestic dust, decaying 
wood, or bird droppings (notably pigeons), enters the 
host by the inhalation of yeast spores. The yeast’s thick 
capsule inhibits the phagocytosis, thereby facilitating the 
pulmonary and blood stream invasion, and therefore 
spreads to different organs.4,7 The clinical features 
vary from asymptomatic infection to life-threatening 
disease.3 Although the respiratory tract is the portal 
of entry, the central nervous system (CNS) is the site 
that is mostly involved5 possibly presenting as cerebral 
cryptococcoma, meningitis, or meningoencephalitis. 
The lungs, eyes, prostate, osteomuscular system, skin, 
and mucosa represent other sites that could possibly 
be involved.1,4 The vast majority of immunocompetent 
patients present isolated pulmonary cryptococcosis.8 
Among them, one-third are symptomless and are 
diagnosed incidentally when a chest x-ray is undertaken 
for any other purpose. However, when symptoms occur, 
they are represented by fever, weight loss, dyspnea, 
cough, mucoid sputum, hemoptysis, and chest pain.3,4,8 
The differential diagnosis between the presentation form 
of the pulmonary nodules or masses involve primary or 
metastatic pulmonary neoplasia, granulomatous diseases 
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of the lung, such as fungal or mycobacterial infections 
and septic embolization.7,9
Imaging findings vary according to the length 
of the disease and the host immune response.9 
Well-circumscribed, non-calcified, non- cavitated, multiple 
or single nodules, unilateral or bilateral, usually subpleural 
within the inferior lobes are the most common radiologic 
finding among the immunocompetent patients,10 unlike 
the imaging findings of the immunocompromised 
patients that seem to present predominantly interstitial 
and alveolar opacities.10,11 These nodules usually 
measure between 0.5 cm and 4 cm. Although already 
described, the lung masses are less common.12 However, 
a Brazilian study showed that pulmonary masses were 
the most frequent finding (64.2%), followed by nodules 
(35.7%).13 Pulmonary consolidation, pleural effusions, 
lymphadenopathy, or cavitation were rarely detected on 
radiography of immunocompetent patients.10,11,14
Diagnosis can be made by direct research of the 
fungus or the cryptococci antigen in the sputum and/or 
bronchoalveolar lavage. The demonstration of the fungus 
may be done in the histopathological examination of 
biopsy specimens or in BAL by India ink, Grocott-Gomori, 
mucicarmine, PAS, and alcian blue stainings. In our 
patient, the BAL research was negative for both the direct 
examination and cultures of the specific pathogens, but 
the histopathological examination yielded the diagnosis 
with the aid of Grocott and mucicarmine stainings.1,3 
Definite diagnosis was made with the isolation of the 
pathogen in culture media. Although a negative result 
does not rule out the diagnosis (sensitivity of 50% in 
pulmonary forms)4 the serum antigenemia determination 
is still used with diagnostic purposes. In our case, the 
serum antigenemia was used to reinforce the necessity 
of the systemic treatment with fluconazole.
Figure 6. A - Pulmonary parenchyma showing a terminal bronchiole with chronic inflammatory infiltrate and dense 
histiocytic infiltration replacing the alveoli (H&E, 100X); B - Necrotic area surrounded by granulomas with epitheliod 
histiocytes and multinucleated giant cells (H&E, 100X); C - Detail of a necrotic area with presence of numerous 
round birefringent structures with a peripheral halo characteristic of Cryptococcus sp. (H&E, 400X); D - Mucicarmine 
staining positive decorating the capsule of the Cryptococcus sp. yeasts (400X).
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A thorough investigation of the CNS involvement 
with neuroimaging and cerebrospinal fluid examination 
is advisable whenever the diagnosis of pulmonary 
cryptococcosis is done in the presence of serum 
antigenemia greater than 1:512 (sensitivity of 95%),4 risk 
factors for disseminated disease, or if the patient presents 
any immunodeficiency.3,15 In the case reported herein, the 
patient did not present any neurologic sign or symptom 
and the neurological examination was normal. She did 
not present any known immunodeficiency, neurological 
examination was normal as well as the brain CT and the 
CD4 count was normal; reason why we did not go on 
investigating the CNS involvement.
The treatment schedule and its duration depend 
on the clinical manifestation as well as on the patient’s 
immune system integrity.3 Even among the asymptomatic 
cases, the treatment reduces the dissemination risk,7 
mainly among the immunosuppressed patients.
The infection confined to the respiratory tract 
should be treated with fluconazole 200 mg/daily15 
for 6–12 months, either for immunocompetent or for 
immunocompromised patients.3 The pulmonary forms 
should always be treated in the presence of symptomatic 
and/or disseminated disease, and if the Cryptococcus 
sp antigenemia results are positive and/or if the patient 
presents any sort of immunosupression.16
Asymptomatic, or patients with disease restricted to 
the lungs, as well as those patients whose lesions have 
been resected, can be thoroughly followed up (with 
clinical and laboratory examinations) without antifungal 
treatment. However, this approach is controversial, since 
some authors advocate specific therapy for pulmonary 
forms in all patients, regardless of the presence of 
symptoms.17
Currently, surgical treatment is not routinely 
recommended for pulmonary infection, except in the case 
of failure of clinical treatment or for the pseudotumoral 
lesions and exudative pleural effusion.16 The diagnosis 
of some cases of cryptococcosis is only made after 
histopathological examination of the surgical specimen 
(pulmonary mass), undertaken in the pursuit of neoplasia. 
In these patients, the total resection can be considered 
therapeutic,18 as aforementioned.
Mild-to-moderate infection confined to the 
respiratory tract may be treated with fluconazole 
from 200 to 400 mg/day for 6 to 12 months for both 
immunocompetent and immunocompromised patients. 
The severe cases, with CNS involvement or disseminated 
disease, should be treated with amphotericin and 
flucytosine, followed by a consolidation treatment phase 
with fluconazole for 12 months in immunocompetent 
patients and for an undetermined period, or until immune 
reconstitution in immunosuppressed patients. The 
persistent positive antigenemia should not be considered 
as criteria for treatment extension.
We emphasize the importance to consider the 
cryptococcoma among the differential diagnosis of 
pulmonary masses, mainly in immunocompetent 
patients. Although cryptococcosis is highly associated 
with immunosuppression, the incidence among the 
immunocompetent patients is not negligible, and 
therefore should never be missed.
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